Who Paid My Doc
Mark Stein
Anesthesiology Berkeley Heights, NJ Medical Doctor
NPI 1417039074 CMS profile 944272
1 Diamond Hill Rd, Berkeley Heights, NJ 07922
General payments
$4,425
Research payments
$0
Ownership & investment interest
$0
Research they led as principal investigator
$7,682
Through program year 2022, Mark Stein of Berkeley Heights, NJ is reported in the CMS Open Payments database as having received $4,425 across 7 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $7,682 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 95th percentile of Anesthesiology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
4 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2022 | General | $750 | 1 | |
| 2021 | General | $1,925 | 3 | |
| 2020 | General | $525 | 1 | |
| 2019 | General | $1,225 | 2 |
Beside peers
- Mark Stein
- Anesthesiology median
- Middle half of Anesthesiology
- National median
In program year 2025, general payments to Mark Stein were reported at $0. Among 18,548 Anesthesiology profiles paid that year, the median was $58 and the middle half received between $26 and $153.
Show as a table
| Year | Mark Stein | Anesthesiology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $1,225 | $72 | $23–$151 | $163 |
| 2020 | $525 | $36 | $17–$120 | $114 |
| 2021 | $1,925 | $49 | $21–$135 | $132 |
| 2022 | $750 | $52 | $22–$144 | $149 |
| 2023 | $0 | $53 | $23–$143 | $160 |
| 2024 | $0 | $55 | $25–$150 | $164 |
| 2025 | $0 | $58 | $26–$153 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Billing to Medicare
Part B · data year 2024 · 20 billing codesPaid by Medicare
$11,256
Medicare patients
98
Services billed
98
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 68% | |
| Arthritis | 47% | |
| Cancer | 32% | |
| Diabetes | 31% | |
| Ischemic heart disease | 27% | |
| Chronic kidney disease | 20% | |
| Osteoporosis | 17% | |
| Atrial fibrillation | 15% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
7 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Anesthesiology in New Jersey
Related records
Anesthesiology in New Jersey
Practitioners in the same specialty and state, ranked by reported value.
All Anesthesiology
Everyone recorded under this specialty, nationwide.
Doctors in New Jersey
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.